Related Experiment Video
Updated: Aug 20, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Safety issues related to emerging therapies for rheumatoid arthritis
1University of Toronto, Canada.
Abstract:
Several novel biologic therapies for rheumatoid arthritis (RA) are emerging that target aspects of the immune system other than tumor necrosis factor (TNF). Two such therapies currently in development include CTLA4Ig (Abatacept) and anti-CD20 monoclonal antibody (Rituximab). CTLA4Ig has been demonstrated to be well tolerated with a good short-term safety profile. Rituximab has also been shown to have a good safety profile in a limited number of RA patients. Further safety data with larger numbers of RA patients treated with Rituximab is required.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Drug Toxicity: Risk factors
Rheumatic Heart Disease I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Therapy
Antianxiety Medications
